Personalized cell therapy shows promise but trial ends early
NCT ID NCT03645928
First seen May 22, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head and neck cancer, or non-small cell lung cancer. The study was terminated early, so the full results are not available, but the approach may still offer hope for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Attikon University General Hospital
Athens, Attica, 12461, Greece
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1011, Switzerland
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Guy's Hospital
London, England, SE19RT, United Kingdom
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Málaga, 29016, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Laiko General Hospital of Athens
Athens, Attica, 11527, Greece
-
MD Anderson at Cooper
Camden, New Jersey, 08103, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Ohio State University
Columbus, Ohio, 43201, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32610, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
The Royal Marsden NHS Foundation Trust
London, England, SW3 6JJ, United Kingdom
-
Universitaetsspital Bern
Bern, 3010, Switzerland
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Diego
La Jolla, California, 92093, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Louisville
Louisville, Kentucky, 40292, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Southern California
Los Angeles, California, 90007, United States
-
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, Schleswig-Holstein, 23538, Germany
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TIL) called lifileucel and LN-145
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This trial was terminated early, so results are limited. TIL therapy is complex and can cause serious side effects, and it may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.